CeriBell (NASDAQ:CBLL) Director Josef Parvizi Sells 25,000 Shares

CeriBell, Inc. (NASDAQ:CBLL) Director Josef Parvizi sold 25,000 shares of the firm’s stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $21.49, for a total transaction of $537,250.00. Following the completion of the sale, the director owned 772,652 shares of the company’s stock, valued at $16,604,291.48. This trade represents a 3.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Josef Parvizi also recently made the following trade(s):

• On Monday, December 8th, Josef Parvizi sold 25,000 shares of CeriBell stock. The stock was sold at an average price of $20.26, for a total value of $506,500.00.

CeriBell Stock Down 1.8%

Shares of NASDAQ CBLL traded down $0.40 during mid-day trading on Wednesday, hitting $21.59. 501,999 shares of the stock traded hands, compared to its average volume of 612,782. The company has a debt-to-equity ratio of 0.12, a quick ratio of 12.25 and a current ratio of 12.65. The company has a market cap of $800.99 million, a price-to-earnings ratio of -14.30 and a beta of 1.35. The stock has a fifty day moving average price of $14.90 and a 200-day moving average price of $14.61. CeriBell, Inc. has a 52 week low of $10.01 and a 52 week high of $28.43.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.06. The company had revenue of $22.59 million during the quarter, compared to analysts’ expectations of $21.78 million. CeriBell had a negative net margin of 63.35% and a negative return on equity of 29.63%. Research analysts anticipate that CeriBell, Inc. will post -2.46 EPS for the current year.

Hedge Funds Weigh In On CeriBell

A number of institutional investors and hedge funds have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in CeriBell during the third quarter valued at $33,000. Tower Research Capital LLC TRC increased its position in shares of CeriBell by 353.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after purchasing an additional 1,801 shares during the last quarter. Ameritas Investment Partners Inc. lifted its stake in shares of CeriBell by 97.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock worth $48,000 after purchasing an additional 1,256 shares during the period. Police & Firemen s Retirement System of New Jersey boosted its holdings in shares of CeriBell by 161.0% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 5,677 shares of the company’s stock worth $106,000 after buying an additional 3,502 shares during the last quarter. Finally, Sherbrooke Park Advisers LLC bought a new stake in CeriBell during the third quarter valued at approximately $135,000.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on CBLL shares. TD Cowen cut their price target on CeriBell from $36.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. Weiss Ratings reissued a “sell (e+)” rating on shares of CeriBell in a research note on Wednesday, October 8th. Canaccord Genuity Group lifted their price target on CeriBell from $29.00 to $30.00 and gave the stock a “buy” rating in a research report on Wednesday. JPMorgan Chase & Co. lowered their price objective on CeriBell from $21.00 to $17.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. Finally, Cowen reissued a “buy” rating on shares of CeriBell in a report on Tuesday, December 9th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, CeriBell has an average rating of “Moderate Buy” and a consensus target price of $24.67.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.